Latest market price
14.85
+0.92+6.60%
OverviewShort InterestFilings
JBIOQT27Jade Biosciences, Inc.·NASDAQ
14.85+6.60%
News
Up 6.6% — Jade Biosciences to Participate in Upcoming Conferences (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE+2.00%$23.43RARE+2.56%$16.72NUVB+2.29%$4.70TRAX+1.65%$45.80NTLA+4.63%$12.20ABSI+5.78%$10.25URGN-0.82%$34.08MAZE+2.22%$31.05
Snapshot
Index—P/E—EPS (ttm)-2.75Insider Own7.75%Shs Outstand63.60MPerf Week-3.93%
Market Cap885.91MForward P/E—EPS next Y-2.92Insider Trans0.00%Shs Float51.97MPerf Month-1.35%
Enterprise Value425.91MPEG—EPS next Q-0.73Short Float21.57%Perf Quarter-34.75%
Income-153.00MP/S—EPS this Y—Short Ratio12.49Perf Half Y-43.19%
Sales0.00P/B2.01EPS next Y—ROA-32.46%Short Interest11.21MPerf YTD-9.72%
Book/sh6.92P/C1.92EPS next 5Y—ROE-49.11%52W High28.00 -46.96%Perf Year41.42%
Cash/sh7.25P/FCF—EPS past 3/5Y—ROIC-37.40%52W Low8.36 77.63%Perf 3Y-96.04%
Dividend Est.2.40 (16.16%)EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility5.08% 5.89%Perf 5Y-97.14%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.86Perf 10Y—
Dividend Ex-DateApr 29, 2025Quick Ratio14.93Sales Y/Y TTM—Profit Margin0.00%RSI (14)39.27Recom2.00
Dividend Gr. 3/5Y—Current Ratio14.93EPS Q/Q11.63%SMA20-1.62%Beta1.74Target Price48.40
Payout0.00%Debt/Eq0.00Sales Q/Q—SMA50-14.76%Rel Volume0.81Prev Close13.93
Employees55LT Debt/Eq0.00EarningsNov 12SMA200-23.62%Avg Volume887.45KPrice14.85
IPO DateJun 30, 2021Option/ShortYes / YesEPS/Sales Surpr.-19.42% —Net Debt/EBITDA—Volume718,189Change6.60%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-11-26ReiteratedJefferies$40 → $48
Jun-15-26InitiatedUBSBuy$45
Jun-02-26ReiteratedPiper Sandler$55
Jun-02-26ReiteratedGuggenheimBuy$32 → $47
May-11-26ReiteratedGuggenheimBuy$14 → $32
May-11-26ReiteratedWedbushOutperform$34
Apr-27-26ReiteratedHC Wainwright & Co.Buy$25 → $45
Mar-06-26ReiteratedStifel Nicolaus$19 → $40
Jan-07-26InitiatedH.CBuy$25
Oct-09-25InitiatedBTIGBuy$28
Latest News· Times ET
Today
Today07:00AM
Jade Biosciences to Participate in Upcoming Conferencesglobenewswire.com
Oct-27-26
Oct-27-2601:45AM
BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price TargetBenzinga
Oct-21-26
Oct-21-2607:00AM
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026globenewswire.com
Oct-01-26
Oct-01-2604:27AM
Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price TargetBenzinga
Sep-30-26
Sep-30-2604:22PM
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcriptseekingalpha.com
07:00AM
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026globenewswire.com
Sep-28-26
Sep-28-2603:29AM
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokeragesdefenseworld.net
Sep-09-26
Sep-09-2611:17AM
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeekingAlpha
Sep-01-26
Sep-01-2607:00AM
Jade Biosciences to Participate in Upcoming Conferencesglobenewswire.com
Aug-19-26
Aug-19-2611:44AM
Jade Biosciences: Duration Is The Real Productseekingalpha.com
Aug-11-26
Aug-11-2605:40AM
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47Benzinga
Aug-10-26
Aug-10-2607:00AM
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com
03:08AM
Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) EstimateBenzinga
Company

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
0000———
Cost of Goods Sold Incl. D&A
0000———
Gross Profit
0000———
Selling, General and Administrative Excl. Other27202117———
Research and Development137935364———
Other Operating Expense0100———
Operating Income-164-114-75-81———
Interest Expense
0000———
Unusual Expense
———————
Non-Operating Income (Expense)11-1456———
Net Income Before Taxes-153-127-70-75———
Income Taxes
0000———
Consolidated Net Income-153-127-70-76———
Net Income From Continuing Operations-153-127-70-76———
Net Income-153-127-70-76———
EPS (Recurring)-2.75-4.06-85.26-100.38———
EPS (Basic, Before Extraordinaries)-2.75-4.06-85.26-100.38———
EPS (Diluted)-2.75-4.06-85.26-100.38———
EBITDA-156-127-69-75———
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding613111———
Market Capitalization90647893792———
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$29.84$23.37$16.90$10.43$3.96● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Frohlich TomChief Executive OfficerMay 16 '25Buy7.406,00044,4006,000May 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.